ReviewPharmaceuticals (Basel, Switzerland)2025

Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors.

Hannes Leupe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.